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PENCIRIAN SUBTIP HIV-1 DAN MUTASI BERKAITAN KERINTANGAN UBAT 
PADA GEN Protease DAN Transkriptase Membalik DI KALANGAN PESAKIT HIV-1 
DI KELANTAN 
 
ABSTRAK 
 
Jangkitan Virus Imunodefisiensi Manusia (HIV) merupakan salah satu penyakit berjangkit 
yang utama di Malaysia. Banyak kajian berkaitan kepelbagaian genetik HIV dan 
pengawasan kerintangan ubat telah dijalankan di Malaysia terutamanya di Kuala Lumpur 
dan Selangor. Walau bagaimanapun, sejak dua dekad yang lalu, masih terdapat kekurangan 
maklumat berkaitan kepelbagaian genetik dan kerintangan ubat di kalangan penghidap HIV 
di Kelantan meskipun negeri ini merupakan antara tiga negeri yang mencatatkan bilangan 
kes jangkitan baru HIV yang tertinggi. Kajian ini menunjukkan terdapat enam subtip HIV-1 
yang wujud di kalangan penghidap HIV di Kelantan dalam pelbagai kumpulan berisiko. 
Subtip tersebut ialah CRF33_01B, subtip B‟, CRF01_AE, CRF53_01B, CRF54_01B dan 
URF CRF01_AE/B. Kajian ini turut menunjukkan dominasi CRF33_01B di kalangan pesakit 
dewasa dan pediatrik serta semua populasi berisiko (penagihan dadah melalui suntikan, 
hubungan heteroseksual, transmisi vertikal). 
 
Perkongsian jarum suntikan merupakan penyumbang terbesar kepada penyebaran jangkitan 
HIV dalam populasi kajian, berbeza dengan kebanyakan penyelidikan lain di Malaysia yang 
melaporkan hubungan seksual sebagai faktor utama penyebaran jangkitan HIV sejak 12 
tahun yang lepas. Pesakit lelaki kekal sebagai majoriti penghidap jangkitan HIV dan 
sebahagian besar jangkitan diperoleh melalui perkongsian jarum suntikan. Walau 
bagaimanapun, kebanyakan pesakit perempuan pula dijangkiti virus HIV melalui hubungan 
seksual. 
 
xv 
 
Analisis kerintangan ubat telah dijalankan menggunakan pangkalan data kerintangan ubat 
HIV Stanford. Daripada 25 pesakit yang tidak menerima rawatan, 40% dijangkiti HIV-1 
yang mengandungi sekurang-kurangnya satu Mutasi Berkaitan Kerintangan (RAMs). 
Berdasarkan garis panduan Pertubuhan Kesihatan Dunia (WHO) pada tahun 2012, bilangan 
RAMs ini menurun kepada 16%. Dua puluh RAMs diperoleh daripada pesakit yang belum 
menerima rawatan dengan 60% daripadanya berkaitan dengan Perencat Transkriptase 
Membalik Bukan Analog Nukleosida (NNRTI) dan 20% masing-masing berkaitan dengan 
Perencat Transkriptase Membalik Analog Nucleosida/Nukleotida (NRTI) dan Perencat 
Protease (PI). RAMs yang paling banyak diperoleh adalah V179D/T (16%), yang mampu 
mengurangkan kerentanan terhadap NNRTI. Sementara itu, menurut pangkalan data 
kerintangan ubat HIV Stanford, 79.7% daripada pesakit yang sedang menerima rawatan 
dijangkiti HIV-1 yang mengandungi RAMs berkaitan dengan NRTI, NNRTI dan PI. Antara 
pesakit yang sedang dirawat, 251 RAMs diperoleh dengan lebih separuh daripadanya 
berkaitan dengan NRTI (55.4%), diikuti oleh NNRTI (37.1%) dan PI (7.6%). Mutasi-mutasi 
yang paling kerap ditemui ialah M184I/V (40.6%), K103N/R/S (37.5%), T215F/H/I/V/Y 
(35.9%) dan D67G/H/N (31.3%). Hanya K103N/R/S yang berkaitan dengan NNRTI, 
manakala yang selebihnya berkaitan dengan NRTI. 
 
Kajian ini mengesahkan dominasi subtip CRF33_01B di negeri Kelantan, seterusnya 
mendedahkan kepelbagaian genetik yang tinggi dengan kewujudan subtip HIV-1 Bentuk 
Rekombinan Beredar (CRF) yang baru dan HIV-1 Bentuk Rekombinan Unik (URFs). 
Pengawasan molekular berterusan perlu dilakukan untuk memantau kehadiran HIV-1 URFs 
yang konsisten di kalangan pesakit HIV. Keputusan daripada analisis kerintangan ubat ini 
mampu meningkatkan pengetahuan berkenaan prestasi ubat Terapi Aktif Antiretrovirus 
(HAART), membantu merangka strategi pemilihan kombinasi ubat HAART yang berkesan 
untuk pesakit yang belum menerima rawatan mahupun yang sedang dirawat dan memberi 
penekanan terhadap keperluan untuk menjalankan ujian kerintangan ubat sebelum 
memulakan atau menukar rawatan HAART. 
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CHARACTERISATION OF CIRCULATING HIV-1 SUBTYPES AND DRUG 
RESISTANCE-ASSOCIATED MUTATIONS IN Protease AND Reverse Transcriptase 
GENES AMONG HIV-1 PATIENTS IN KELANTAN 
 
ABSTRACT 
 
Human Immunodeficiency Virus (HIV) infection is one of major infectious diseases in 
Malaysia. A number of studies pertaining to genetic diversity and drug resistance 
surveillance have been performed in Malaysia, especially in Kuala Lumpur and Selangor. 
However, in the past two decades, there is a lack of knowledge on HIV-1 diversity and drug 
resistance among people living with HIV (PLHIV) in Kelantan although this state is among 
the top three states reporting the highest number of new HIV cases annually. This study 
demonstrated that among PLHIV in Kelantan, there were six HIV-1 subtypes circulating in 
different risk groups. These subtypes were CRF33_01B, B‟ subtype, CRF01_AE, 
CRF53_01B, CRF54_01B and URF CRF01_AE/B. Additionally, this study showed the 
predominance of CRF33_01B subtype among adult and paediatric patients and all risk 
populations (Intravenous drug use (IDUs), heterosexual contact and vertical transmission).  
 
Sharing needle was found to be the main contributor for HIV dissemination in study 
population, different than other studies in Malaysia which reported sexual contact as the 
main factor of HIV transmission since 12 years ago. Majority of HIV patients continued to 
be male who acquired the infection mostly through sharing needle. In contrast, female 
patients were infected with HIV via sexual contact. 
 
Drug resistance analysis was carried out based on Stanford HIV drug resistance database. 
From 25 treatment-naive patients, 40% were infected by HIV-1 containing at least one 
transmitted Resistance-associated mutations (RAMs). When analysed against World Health 
Organisation (WHO) consensus, the value was reduced to 16%. Twenty transmitted RAMs 
xvii 
 
were harvested from treatment-naive patients, with 60% were associated with Non-
nucleoside Reverse Transcriptase Inhibitor (NNRTI), and 20% each were associated with 
Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (NRTI) and Protease Inhibitor (PI). 
The most commonly observed transmitted mutation was V179D/T (16%), which may reduce 
drug susceptibility to NNRTI. Meanwhile, according to Stanford HIV drug resistance 
database, 79.7% of patients currently receiving treatment carrying HIV-1 containing 
acquired RAMs against NRTI, NNRTI and PI. Among treated patients, 251 acquired RAMs 
were obtained with more than half were associated with NRTI (55.4%), followed by NNRTI 
(37.1%) and PI (7.6%). The most frequent mutations observed were M184I/V (40.6%), 
K103N/R/S (37.5%), T215F/H/I/V/Y (35.9%) and D67G/H/N (31.3%). Only K103N/R/S 
was associated with NNRTI while the rest of mutations were associated with NRTI. 
 
The present study confirms the high prevalence of CRF33_01B in Kelantan state and reveals 
a high genetic diversity with the presence of newly described HIV-1 Circulating 
Recombinant Forms (CRFs) and HIV-1 Unique Recombinant Forms (URFs). Continuous 
molecular surveillance should be performed to monitor further emergence of HIV-1 URFs. 
Result from drug resistance analysis enhances the knowledge pertaining to Highly Active 
Antiretroviral Therapy (HAART) performance, helps in designing effective HAART 
strategy on treatment-naive and treated patients and subsequently emphasises the need to 
commence drug resistance testing prior to starting or changing HAART treatment. 
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CHAPTER ONE 
INTRODUCTION 
 
1.1 Overview of HIV/AIDS 
1.1.1 Emergence of HIV/AIDS 
Acquired Immune Deficiency Syndrome (AIDS) was first reported in 1981 with the name 
Gay Related Immunodeficiency Syndrome (GRID) before it was replaced with the current 
name, AIDS in September 1982 by the United States Centers for Disease Control and 
Prevention (CDC) (Bell et al., 2011). Initial report described five cases of Pneumocystis 
carinii Pneumonia (PCP) implicated a group of young gay men in Los Angeles. PCP is a rare 
opportunistic infection that is known to occur in people with very compromised immune 
systems (Stolley and Glass, 2009; Bell et al., 2011). Soon, some of the infected gay men 
developed a rare skin cancer called Kaposi‟s sarcoma (Hoffmann et al., 2007; Hoffmann and 
Rockstroh, 2009; Stolley and Glass, 2009; Zuckerman et al., 2009). At that time, CDC had 
no official name and the causative agent of the disease.  One year later, two groups of 
researchers, Robert Gallo group from United States and Luc Montaigner and Barré-Sinoussi 
group from France (Hoffmann and Rockstroh, 2009), proposed the name for the virus that 
causes AIDS based on the different hypothesises in which came out from variable 
symptoms. 
 
In 1983, Robert Gallo group from the United States had declared that a novel 
retrovirus named Human T-lymphotropic virus Type III (HTLV-III) may have been infecting 
AIDS patients since HTLV-III has a similar structure with other HTLVs (Gallo et al, 1983). 
In the same year in France, Luc Montaigner and Barré-Sinoussi group had named the virus 
Lymphadenopathy-associated Virus (LAV) from their own isolate taken from a patient 
suffering from swelling lymph nodes at the neck and physical weakness (two common 
symptoms of AIDS) as a causative agent for AIDS (Barré-Sinoussi et al., 1983). As these 
two viruses proved to be the same, the term Human Immunodeficiency Virus (HIV) was 
2 
 
officially adopted in 1986 and both Gallo and Montagnier groups are credited as co-
discoverers (Lerner and Wilmoth, 2003; Hoffmann et al., 2007; Zuckerman et al., 2009). 
 
In Malaysia, HIV case was first reported in 1986 with a total of three cases while 
AIDS was first discovered in a patient in 1987, one year after the Ministry of Health 
established a national AIDS task force. This patient was diagnosed and confirmed HIV 
positive by Enzyme-linked Immunosorbent Assay (ELISA) and Western Blot tests. The 
patient was a 45 years old man of Malaysia origin who had been living overseas for the past 
30 years and was infected due to multiple sexual partners ten years prior to entering AIDS 
stage (Goh et al., 1987). 
 
From 1986 until December 2011, a total of 94 841 HIV cases were reported, 17 686 
people living with HIV had advanced to AIDS and 14 986 people had died from AIDS 
related diseases making the total number of  people  living with HIV in this country to 79 
855 (Ghani et al., 2012; Ngadiman et al., 2012). HIV cases peaked in 2002 and then showed 
a declining pattern, partly due to the harm reduction programmes, particularly Needle and 
Syringe Exchange Programme (NSEP) and Methadone Maintenance Therapy (MMT) 
(Figure 1.1) (Ghani et al., 2012). In recent years, interestingly, new cases of HIV infection 
showed shifted trends; an increased of female to male ratio and heterosexual transmission of 
the virus (Feary, 2011; Ghani et al., 2012).The female to male ratio of new HIV infections 
had shifted tremendously from 1:99 in 1990 to 1:10 and 1:4 in 2000 and 2011, respectively. 
This change has an impact on the risk factors trend in new HIV cases, where sexual 
transmission replaces transmission via injecting drug use as the major route of HIV 
transmission in Malaysia (Ghani et al., 2012). 
 
Selangor, Johor and Kelantan are the three states in Malaysia which constantly 
report high new HIV cases annually. Kelantan is located on the east coast of Peninsular 
Malaysia and shares border with Thailand, one of the Southeast Asia countries with high 
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new HIV cases. In the past ten years, injecting drug use was the main mode of HIV 
transmission in Kelantan, Terengganu and Pahang. However, in some states in northern 
(Perlis, Kedah, Penang and Perak) and southern (Negeri Sembilan, Melaka and Johore) 
regions, the major route of HIV infection had shifted to sexual transmission, starting from 
2002. Similar observation has been reported in the western region states (Selangor and Kuala 
Lumpur) (Ghani et al., 2012; Ngadiman et al., 2012).  
 
 
 
 
 
 
 
 
 
 
Figure 1.1:   Reported new HIV case and AIDS-related deaths in Malaysia (1986 – 2011).  
Adapted from: Malaysia 2012 Global Aids Response Progress Report, 2012. 
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1.1.2 Origin of HIV 
Scientists believe that HIV-1 was originated from West Africa and subsequently spread to 
Europe and the United States through Caribbean (Lerner  and Wilmoth, 2003). HIV-1 results 
from multiple cross-species transmissions of Simian Immunodeﬁciency Viruses (SIVs) 
which naturally infects African primates. The cross-species transmission of SIV into human 
occurs through hunting and deforestation activities which increase the contact between 
humans and SIV infected primates (Kalish et al., 2005).  
 
SIV is a weak virus and easily suppressed by human immune system within weeks 
of infection before the virus has sufficient time to overcome human immune system. 
However, several transmissions between humans (horizontal transmissions) led to certain 
viral mutation that could overcome human immune system, resulting in SIV mutated to HIV 
(Marx et al., 2001). HIV-1 is believed to be originated from chimpanzee infected with SIV. 
Common chimpanzee (Pan troglodytes) has been shown to be the true reservoir of SIV 
(Sharp and Hahn, 2011). There are several types of SIV based on their host origin, but the 
virus that infects Chimpanzee is known as SIVcpz. The SIVcpz strains fall into two 
subspecies-speciﬁc lineages, termed SIVcpzPtt (from Pan troglodytes troglodytes) and 
SIVcpzPts (Pan troglodytes schweinfurthii). SIVcpzPtt is closely related to HIV-1 (Sharp 
and Hahn, 2011). 
 
1.1.3 Mode of transmission 
HIV/AIDS is a bodily fluid-borne infection. The virus could not be transmitted directly via 
air, water, food and skin touch. HIV/AIDS could only be transmitted to a healthy person via 
three major routes; unsafe sex with an HIV-infected partner (both homo and heterosexual), 
sharing injection needle with an HIV-infected partner and vertical transmission of HIV from 
infected mother to baby during pregnancy, delivery, or through breast milk feeding. All other 
transmission routes such as blood or blood product transfusion and needle prick injury are 
rare or extremely rare (Hoffmann and Rockstroh, 2012). 
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Heterosexual transmission was proposed as a transmission route for AIDS in 1983 
by Luc Montagnier. At the beginning of disease dissemination, most healthy individuals 
were infected following sexual intercourse, especially through heterosexual contact (Bell et 
al., 2011). In Malaysia, half of new HIV cases are contributed by sexual transmission 
(hetero, homo and bisexual collectively) and has replaced injecting drug use as the major 
transmission route from 2010 onwards (Ghani et al., 2012). Moreover, heterosexual 
transmission is the major cause of HIV infection among Malaysian women since 87% of 
them are infected with HIV through their partners (Ngadiman et al., 2012). 
 
In Malaysia, males continue to represent the majority (90%) of cumulative HIV 
cases despite showing a significant decline beginning 2003. In contrast, an opposite trend has 
been observed in females. Among males, 48% acquired HIV via injecting drug use (IDU) 
and 47% through sexual transmission (Ghani et al., 2012; Ngadiman et al., 2012). In 2011, 
new HIV cases due to injecting drug use had declined significantly from eight years ago (70-
80%) to 38.7%. The reduction of newly reported HIV cases caused by injecting drug use is 
attributed to Needle Syringe Exchange Program (NSEP) and Methadone Replacement 
Therapy (Ngadiman et al., 2012). 
 
The first HIV infection involving children was reported in 1982. The infants 
acquired HIV from their mother and this vertical transmission at present is recognised as a 
major mode of HIV transmission in children (Bell et al., 2011). In Malaysia, new HIV cases 
due to vertical transmission have doubled to two percent in 2011 compared with the previous 
year (Ghani et al., 2012). 
 
1.2 AIDS and opportunistic infections 
Person who is infected by HIV are recognised as HIV carrier and now, the term has changed 
to people living with HIV/AIDS (PLWHA or PLHIV) to reduce stigma and discrimination 
by society. At least 85% of people who are diagnosed with HIV but do not receive treatment 
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will progress to AIDS within an estimated of eight to 12 years (Stolley and Glass, 2009) and 
the duration may become shorter depending on patient health care and nutritional status. 
AIDS is the stage when the immune system is badly damaged, resulting in the body becomes 
vulnerable to opportunistic infections. PLHIV will progress to AIDS stage if they have CD4 
count lower than 200 cells per mm
3
 and show at least one of AIDS-defining diseases or 
symptoms (Stolley and Glass, 2009; AIDS.gov, 2009). However, the criteria for diagnosing 
AIDS may differ depending on individual country guidelines (Avert.org, 2005b). People 
who are diagnosed with AIDS usually survive for about three years without treatment, but 
may only live for one year if they are infected with  potentially fatal opportunistic infections 
such as Kaposi's sarcoma, tuberculosis, toxoplasmosis and pneumocystis carinii pneumonia 
(PCP) (AIDS.gov, 2009).   
 
Opportunistic infections can be caused by bacteria, viruses, fungi, protozoans and 
parasites that are typically brought under control by a healthy and functional immune system 
(Holmes et al., 2003; Kayser et al., 2005). Opportunistic infections related to AIDS or 
termed as AIDS-defining diseases for HIV patients who have advanced to AIDS. Some of 
the world's most common HIV-related opportunistic infections and diseases include: 
 
I. Bacterial diseases such as tuberculosis (TB) caused by Mycobacterium tuberculosis, 
Mycobacterium avium complex (MAC), bacterial pneumonia and septicaemia (blood 
poisoning or bacteraemia) caused by Escherichia coli, Pneumococcus, Klebsiella, 
Pseudomonas, Staphylococcus and Streptococcus (Avert.org, 2005a; Kayser et al., 
2005; Better Health Channel, 2012), 
 
II. Protozoal diseases such as toxoplasmosis caused by Toxoplasma gondii, 
microsporidiosis, cryptosporidiosis, isopsoriasis and leishmaniasis caused by 
microsporidian species, Cryptosporidium, Isospora belli and genus Leishmania 
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protozoa, respectively (Avert.org, 2005a; Kayser et al., 2005; Pubmed Health, 
2012), 
 
III. Fungal diseases such as PCP caused by pneumocystis jirovecii, candidiasis, 
cryptococcosis and penicilliosis caused by candida albicans (most frequent), 
Cryptococcus neoformans, and  Penicillium marneffei, respectively (Avert.org, 
2005a; Kayser et al., 2005), 
 
IV. Viral diseases such as those caused by cytomegalovirus, herpes simplex (HSV-1 and 
HSV-2) and herpes zoster virus (Avert.org, 2005a; Kayser et al., 2005), and 
 
V. HIV-associated malignancies such as Kaposi's sarcoma, B-cell lymphoma Epstein-
Barr virus (EBV)-positive and squamous cell carcinoma (Avert.org, 2005a; Kayser 
et al., 2005). 
 
TB is the principal cause of death among people living with HIV (Hoffmann and 
Rockstroh, 2009; UNAIDS, 2010). In 2009, there were an estimated of 380 000 deaths from 
TB among people with HIV. In some countries, the HIV prevalence among people with TB 
is as high as 80% (UNAIDS, 2010). In Malaysia, about 20 666 new TB cases were registered 
in 2011 and about 3.2% of them also have HIV co-infection. From a total of 52 205 people 
infected with TB until 2011, about eight percent were TB/HIV co-infected (Ngadiman et al., 
2012). Penicilliosis caused by Penicillium marneffei is the most common opportunistic 
infection in AIDS patients in Southeast Asia and present primarily in lungs (Kayser et al., 
2005). 
 
1.3 Molecular epidemiology and diversity of HIV 
HIV is a positive sense single-stranded RNA virus, a member of Lentivirus genus and in the 
Retroviridae family (Carter and Saunders, 2007; Cann, 2011). HIV is classified into two 
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major groups; HIV-1 and HIV-2. HIV-1 is originated from SIV found in common 
chimpanzees while HIV-2 is isolated from SIV infected-sooty mangabeys in 1986 
(Zuckerman et al., 2009). HIV-1 is distantly related to SIV compared with HIV-2 
(Chakrabarti et al., 1987; Reeves and Doms, 2002). HIV-1 is more virulent than HIV-2 since 
the former virus has greater infectivity capability and infects host cell more efficiently than 
HIV-2 (Donnelly et al., 1993; Gilbert et al., 2003) and thus, responsible for most HIV/AIDS 
pandemic. 
 
HIV-1 variants can be divided into group M, N, O, and P. Each group arose from a 
separate transmission of SIVcpz into humans, except for group P which came from SIVgor 
infecting western gorilla (Gorilla gorilla) (Sharp and Hahn, 2011). Group M which means 
„major‟ or „main‟, is the first to be discovered and primarily responsible for the global 
HIV/AIDS pandemic and has been found virtually in every country on the globe (Karim and 
Karim, 2010; Sharp and Hahn, 2011).  
 
Group M is further divided into subtypes or clades, sub-subtypes, intersubtype 
recombinant forms, circulating recombinant forms (CRFs) and unique recombinant forms 
(URFs) (Taylor et al., 2008). The subtypes are represented by letters from A to K, aside from 
E and I. Sub-subtypes are derived from subtype A and F only. CRFs are the outcome from 
recombination between viruses from different subtypes and are assigned by a number. So far, 
there are nine subtypes and 58 CRFs identified to cause the HIV/AIDS pandemic (Taylor et 
al., 2008; Los Alamos, 2013). Table 1.1 shows the complete list of CRFs. Recent estimates 
show that subtype C accounted for almost half (48%) of all worldwide infections, followed 
by subtypes A (12%), B (11%), CRF02_AG (8%), CRF01_AE (5%), subtype G (5%) and D 
(2%). Subtypes F, H, J and K together cause less than one percent of global infections. Other 
CRFs and URFs are each responsible for four percent of worldwide infections. Combined all 
CRFs and URFs contribute to 20% of global HIV infections (Hemelaar et al., 2011).  
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Table 1.1   Complete list of specific CRFs of HIV-1 (Last update: 14 November 2013). 
Name Reference strain Subtypes Author(s) 
CRF01_AE CM240 A, E J.K. Carr 
CRF02_AG IbNG A, G J.K. Carr 
CRF03_AB Kal153 A, B K. Liitsola 
CRF04_cpx 94CY032 A, G, H, K, U D. Paraskevis 
CRF05_DF VI1310 D, F T. Laukkanen 
CRF06_cpx BFP90 A, G, J, K R. B. Oelrichs 
CRF07_BC 97CN54 B', C R. Wagner 
CRF08_BC 97CNGX-6F B', C F.E. McCutchan 
CRF09_cpx 96GH2911 A, G, U F.E. McCutchan 
CRF10_CD TZBF061 C, D I.N. Koulinska 
CRF11_cpx GR17 A, E, G, J, U M. Peeters 
CRF12_BF ARMA159 B, F1 J.K. Carr 
CRF13_cpx 96CM-1849 CRF01, A, G, J, U K. Wilbe 
CRF14_BG X397 B, G R. Najera 
CRF15_01B 99TH.MU2079 CRF01, B F.E. McCutchan 
CRF16_A2D 97KR004 A2, D U. Visawapoka 
CRF17_BF ARMA038 B, F1 J.K. Carr 
CRF18_cpx CU76 A1, F, G, H, K, U M. Thomson 
CRF19_cpx CU7 A1, D, G M. Thomson 
CRF20_BG Cu103 B, G M. Thomson 
CRF21_A2D 99KE_KER2003 A2, D F.E. McCutchan 
CRF22_01A1 02CMLT72 CRF01, A1 J.K. Carr 
CRF23_BG CB118 B, G M. Thomson 
CRF24_BG CB378 B, G M. Thomson 
CRF25_cpx 02CM_1918LE A, G, U J.K. Carr 
CRF26_AU 02CD_MBTB047 A, U M. Peeters 
CRF27_cpx 04FR-KZS A, E, G, H, J, K, U M. Peeters 
CRF28_BF BREPM12609 B, F1 R. Diaz 
CRF29_BF BREPM16704 B, F1 R. Diaz 
CRF30_0206 00NE36 CRF02, CRF06 M. Peeters 
CRF31_BC 04BR142 B, C M. Soares 
CRF32_06A1 EE0369 CRF06, A1 M. Adojaan 
CRF33_01B 05MYKL007 CRF01, B K.P. Ng and K.K. Tee 
CRF34_01B OUR2275P CRF01, B F.E. McCutchan 
CRF35_AD AF095 A, D F.E. McCutchan 
CRF36_cpx NYU830 CRF01, CRF02, A, G R. Powell 
CRF37_cpx NYU926 CRF01, CRF02, A, G, U R. Powell 
CRF38_BF UY03_3389 B, F1 C. Lopez-Galindez 
CRF39_BF 03BRRJ103 B, F1 M.G. Morgado 
CRF40_BF 05BRRJ055 B, F1 M.G. Morgado 
 
Adapted from: Los Alamos (http://www.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs. 
html ). Accessed on: 17 February 2014 
 
10 
 
Table 1.1   Continued 
Name Reference strain Subtypes Author(s) 
CRF41_CD CO6650V1 C, D S. Tovanabutra 
CRF42_BF luBF_13_05 B, F1 J-C. Schmit 
CRF43_02G J11223 CRF02, G C. Brennan 
CRF44_BF CH80 B, F1 M. Thomson 
CRF45_cpx 04FR.AKU A, K, U M. Peeters 
CRF46_BF 01BR087 B, F1 S. S. Sanabani 
CRF47_BF P1942 B, F1 M. Thomson 
CRF48_01B 07MYKT014 CRF01, B Y. Takebe 
CRF49_cpx N28353 A1, C, J, K, U T. de Silva and M. Cotten 
CRF50_A1D  - A1, D G. Foster 
CRF51_01B HM021 CRF01, B O.T. Ng 
CRF52_01B M043 CRF01, B J. Li 
CRF53_01B  - CRF01, B K.K. Tee 
CRF54_01B  - CRF01, B K.K. Tee 
CRF55_01B  - CRF01, B X. Han 
CRF57_BC 1439 B, C L. Li 
CRF59_01B 09LNA423 CRF01, B X. Han 
CRF61_BC JL100010 B, C X. Li 
 
Adapted from: Los Alamos (http://www.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs. 
html ). Accessed on: 17 February 2014 
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Intersubtype recombinant form is a mosaic strains that have segments from two or more 
subtypes alternating across their genome (Taylor et al., 2008). CRF is defined as specific 
intersubtype recombinants from at least three epidemiologically unlinked variants that are 
monophyletic spreading in a population and share an identical genetic structure (Taylor et 
al., 2008; Holguin et al., 2008). URF variants are widely distributed worldwide, with 
recombination breakpoints different from those of CRFs and they have been found in not 
more than three infected persons. Recombination events result from co-infection and/or 
superinfection of host cells with different HIV variants. URFs occur especially in 
populations where multiple subtypes co-circulate (Holguin et al., 2008). 
 
Group O (outlier) was identiﬁed in 1990 from two Cameroonian AIDS patients 
living in Belgium and is much less prevalent than group M (Leys et al., 1990; Gurtler et al., 
1994). It represents less than one percent of global HIV-1 infections (Mauclère et al., 1997), 
and largely restricted to Cameroon, Nigeria, Gabon, Senegal, Togo, Chad and Niger (Peeters 
et al., 1997). However, the origin of HIV-1 group O remains unknown because there are no 
ape viruses that are closely related to this group. Therefore, HIV-1 group O could either be 
of chimpanzee or gorilla origin (Sharp and Hahn, 2011).  
 
Group N (non-M, non-O) was discovered in 1998 from a Cameroonian woman with 
AIDS (Simon et al., 1998). This group of virus is even less prevalent than group O. Until 
now, only 13 cases of group N infection have been documented, all in individuals from 
Cameroon (Vallari et al., 2010).  
 
Finally, group P was discovered in 2009 in a Cameroonian woman living in France 
(Plantier et al., 2009). In 2011, Vallari et al. found another case of group P from extensive 
screening in Cameroon from 2006 to 2009. Until present, there are only two known cases of 
HIV group P infections with one person for each case. 
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1.4 Diagnosis of HIV 
The first test for HIV detection was developed by Robert Gallo and co-workers and was 
approved in 1985 by the Food and Drugs Administration (FDA) in the United States. 
Sensitivity and specificity are crucial in determining the accuracy of the test. Sensitivity is 
defined as the ability to correctly identify positive samples as positive, whereas specificity 
measures its ability to correctly identify negative samples as negative (Hoffmann et al., 
2007). Generally, diagnosis of HIV could be done via detection of antibody, antigen or viral 
nucleic acid (Kayser et al., 2005).  
 
1.4.1 Antibody detection 
HIV antibody testing detects the presence of HIV-specific antibodies and consists of at least 
two different assays; a screening test and a confirmatory test. Most screening tests are based 
on the ELISA principle. Screening tests should be highly sensitive (close to 100%) to 
minimize false negative result (Hoffmann et al., 2007).  
 
ELISA is a qualitative test, used to detect the presence of antibodies specific to HIV. 
Typically, the screening test result is reported as „reactive‟ rather than „positive‟ to avoid 
misunderstanding since „reactive‟ sample later needs to undergo confirmatory test before a 
patient is diagnosed as HIV positive (Hoffmann et al., 2007; Hoffmann and Rockstroh, 
2012). 
 
Western Blot is usually carried out to confirm reactive sample and considered as a 
gold standard for validation of HIV test results (Zuckerman et al., 2009). Interpretation of 
the result differs in different countries such as United States and Germany. According to 
WHO recommendation, result of a Western blot is considered positive if at least two env 
proteins (gp41, gp120 and gp160) are observed (Hoffmann et al., 2007; Hoffmann and 
Rockstroh, 2012). 
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Apart from western blot, other tests that could be used as confirmatory assays are 
immunofluorescence assay (IFA), line immunoassay (LIA) and second antibody test 
(Avert.org, 2005c). IFA is a qualitative assay and uses fluorescence microscope to detect 
HIV antibody. IFA is less expensive compared with Western Blot for mass use and thus, 
suitable for limited financial resources countries (Van Dyck et al., 1999). In LIA, 
recombinant or synthetic peptide antigens are applied on a nitrocellulose strip, rather than 
electrophoresed as in the Western blot. Moreover, this assay is commonly used in Europe, 
reduces sample cross-contamination and the results are as accurate as the Western Blot 
(Avert.org, 2005c).  
 
HIV antibody testing is only useful two weeks after a patient acquires HIV infection. 
However, detection rate at this point of time is low. Sensitivity of HIV antibody testing 
however continues to increase after four, six, eight and 12 weeks post infection in 60-65%, 
80%, 90% and 95% of cases, respectively (Hoffmann and Rockstroh, 2012). Most patients 
develop detectable HIV antibodies within six to 12 weeks of infection but this may take up 
to six months in auto-immune disorder patients (Avert.org, 2005c). 
 
1.4.2 Antigen detection 
In HIV antigen test, a viral protein, usually capsid protein p24 is detected in serum. The p24 
antigen is detectable in serum about five days before seroconversion (the first occurrence of 
specific antibodies), which is about two weeks after transmission. However, antigen 
detection is not useful after eight to 12 weeks upon transmission since HIV enters stable 
latency period during this point of time and p24 antigen will be detectable again months or 
years later (Hoffmann et al., 2007; Hoffmann and Rockstroh, 2012).  
 
Simultaneous detection of HIV antigen and antibody is applied in fourth generation 
diagnosis test and acts as a screening test. Reactive result from this test will be confirmed 
using Western Blot (Hoffmann et al., 2007; Hoffmann and Rockstroh , 2012). The fourth 
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generation test is highly accurate and capable of diagnosing people exposed to HIV infection 
11 days to one month post infection (Avert.org, 2005c). 
 
1.4.3 Nucleic acid test 
HIV nucleic acid test (NAT) detects the genetic material of HIV. Similar to HIV antigen 
assay, the test could detect HIV in the blood within two or three weeks of infection. 
However, the test is not frequently used since it is very expensive and requires trained 
personal compared with a standard antibody test. The nucleic acid test usually detects and 
amplifies at least one of several target sequences located specifically in HIV target genes 
such as pol, gag and env (Avert.org, 2005c).  
 
For newborns with suspected vertical HIV transmission, HIV NAT is mostly 
preferred test than antibody based assay since maternal antibodies may remain detectable in 
infants until around the age of 18 months, resulting in false-positive results. At least two 
negative NAT results are required to confirm a newborn is free from HIV infection. The first 
HIV NAT should be performed after the first month of life (sensitivity 96%, specificity 
99%), while the second test should be conducted after the baby is three months old 
(Hoffmann and Rockstroh, 2012). 
 
1.5 Treatment 
1.5.1 Drug classes 
At present, there is no antiretroviral (ARV) drug that could effectively treat HIV infection. 
The ARVs currently available in the market could only reduce the viral load but could not 
completely eliminate them. In 1987, the first antiretroviral agent, Zidovudine (AZT, 
Retrovir®) was licensed for the treatment of HIV (Hoffmann and Rockstroh, 2009) and was 
the first tested on humans (Hoffmann and Rockstroh, 2012). Later, between 1991 and 1994, 
more drugs including Zalcitabine (ddC), Didanosine (ddI) and Stavudine (d4T) were 
introduced. During early discovery period of ARV drug, physicians used monotherapy as a 
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sole treatment for HIV patients despite being ineffective due to limited number of drugs 
available. However, using one nucleoside analogue drug alone could not suppress HIV for 
long. When more new ARVs were discovered, dual therapy, a combination of two 
nucleoside analogues was introduced in 1995 and proved to be more effective than 
monotherapy. Since then, more new antiretroviral agents from other drug classes were 
introduced and licensed, including Saquinavir, Ritonavir and Indinavir from protease 
inhibitor drug class and Nevirapine from non-nucleoside reverse transcriptase inhibitor drug 
class (Hoffmann and Rockstroh, 2012).  
 
  ARV acts by targeting various genes responsible for HIV life cycle such as pol, 
integrase and env. From these three target genes, ARV is divided into five different classes; 
Nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside and 
nucleotide reverse transcriptase inhibitor (NNRTI), and protease inhibitor (PI) which target 
pol gene, entry inhibitors that act on env gene and lastly, integrase inhibitors, which target 
integrase gene (Hoffmann and Rockstroh, 2012). As of 2012, there are 31 individual or 
combination ARVs licensed for HIV treatment (Table 1.2). 
 
NRTI targets the HIV enzyme reverse transcriptase by acting as a competitive 
inhibitor. NRTI competes with natural nucleosides to bind with reverse transcriptase since its 
structure is similar to natural nucleosides. By binding to reverse transcriptase, NRTI halts 
elongation of Deoxyribonucleic acid (DNA) strand by preventing formation of 
phosphodiester bond that bind phosphate group in nucleosides to 3‟ end of elongated DNA 
strand (Men´endez-Arias, 2008; Hoffmann and Rockstroh, 2012). So far, seven ARVs from 
NRTI class have been approved and used. 
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Table 1.2   Antiretroviral drugs approved by FDA. 
Drug Abbrev. Trade 
name 
Manufacturer Year 
approved 
Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTIs) 
Zidovudine AZT Retrovir GlaxoSmithKline March 1987 
Didanosine ddl Videx Bristol-Myers Squibb Oct. 1991 
Stavudine d4T Zerit Bristol-Myers Squibb June 1994 
Lamivudine 3TC Epivir GlaxoSmithKline Nov. 1995 
Abacavir ABC Ziagen GlaxoSmithKline Dec. 1998 
Tenofovir TDF Viread Gilead Sciences Oct. 2001 
Emtricitabine FTC Emtriva Gilead Sciences July 2003 
Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 
Nevirapine NVP Viramune Boehringer Ingelheim June 1996 
Delavirdine DLV Rescriptor Pfizer April 1997 
Efavirenz EFV Sustiva Bristol-Myers Squib Sept. 1998 
Etravirine ETR Intelence Tibotec Jan. 2008 
Rilpivirine RPV Edurant Janssen Pharmaceuticals, 
Inc 
May 2011 
Protease Inhibitors (PIs) 
Saquinavir SQV Invirase Hoffmann-La Roche Dec. 1995 
Ritonavir RTV Norvir Abbott Laboratories March 1996 
Indinavir IDV Crixivan Merck March 1996 
Nelfinavir NFV Viracept Agouron Pharmaceuticals March 1997 
Lopinavir/ritonavir LPV/r Kaletra Abbott Laboratories Apr. 2001 
Atazanavir ATV Reyataz Bristol-Myers Squibb June 2003 
Fosamprenavir FPV Lexiva GlaxoSmithKline Oct. 2003 
Tipranavir TPV Aptivus Boehringer Ingelheim June 2005 
Darunavir DRV Prezista Janssen Pharmaceuticals, 
Inc 
June 2006 
Integrase Inhibitors 
Raltegravir RAL Isentress® Merck Oct. 2007 
Elvitegravir EVG - Gilead Sciences Aug. 2012 
Entry Inhibitors 
Enfuvirtide T-20 Fuzeon Hoffmann-La Roche, 
Trimeris 
March 2003 
Maraviroc MVC Celsentri®, 
Selzentry® 
Pfizer Aug. 2007 
 
Adapted from: AIDS info (2012) and Hoffmann and Rockstroh (2012) 
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Table 1.2   Continued 
Drug Abbrev. Trade 
name 
Manufacturer Year 
approved 
Combination drugs 
Lamivudine,  
Zidovudine 
CBV Combivir GlaxoSmithKline Sept. 1997 
Abacavir, 
lamivudine, 
zidovudine 
TZV Trizivir GlaxoSmithKline Nov. 2000 
Abacavir, 
lamivudine 
KVX Epzicom GlaxoSmithKline Aug. 2004 
Emtricitabine,  
Tenofovir 
TVD Truvada Gilead Sciences Aug. 2004 
Efavirenz, 
Emtricitabine, 
Tenofovir 
ATP Atripla Bristol-Myers Squibb,  
Gilead Sciences 
July 2006 
Rilpivirine, 
Emtricitabine, 
Tenofovir 
CPL Complera Gilead Sciences Aug. 2011 
Elvitegravir, 
Cobicistat,  
Emtricitabine, 
Tenofovir  
- Stribild Gilead Sciences Aug. 2012 
 
Adapted from: AIDS info (2012) and Hoffmann and Rockstroh (2012) 
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 NNRTI also targets HIV reverse transcriptase. However, unlike NRTI, NNRTI binds 
to an allosteric site of the enzyme. NNRTI binding causes structural change in the active site 
of reverse transcriptase binding site thus making the enzyme inaccessible for natural 
nucleoside (Hoffmann and Rockstroh, 2012). There are three first-generation NNRTIs; 
Nevirapine, Delavirdine and Efavirenz which were introduced between 1996 and 1998. 
Recently, there are two newly approved NNRTIs, Etravirine (2008) and Rilpivirine (2011). 
Nevirapine and Efavirenz are the most widely prescribed NNRTI since they are as effective 
as or better than ARV from PIs group in naive and slightly in treatment-experienced patients 
and less expensive compared with PIs. Apart from AZT, Nevirapine is also prescribed to 
pregnant women as an alternative (Page et al., 2006). 
 
HIV protease cuts the viral gag-pol polyprotein into functional subunits which are 
crucial for maturation of new virions. Thus, blocking this stage will be one of the appropriate 
strategies to inhibit viral replication. PIs bind exactly into active site of HIV protease to 
block the enzyme function. Initially, PIs were criticised for their high pill burden and side 
effects but with several PIs improvement in reducing dose taking, they remain as essential 
component of ARV treatment (Hoffmann and Rockstroh, 2012). Saquinavir is the first 
protease inhibitor approved by the FDA on 1995. In term of efficacy, Saquinavir is the 
weakest while Ritonavir is the strongest protease inhibitor. At present, Ritonavir is used as a 
booster for the other PIs. Boosted PIs are useful in reducing the frequency and number of 
pills to be taken daily, moreover, some PIs can now be used in once-daily regimens. PIs 
boosted with Ritonavir are usually indicated by a “/r” after the drug name and are recognised 
as second generation drugs (Martinez-Cajas and Wainberg, 2007). For example, Lopinavir 
boosted with Ritonavir is written as “Lopinavir/r” or “(LPV/r)”. So far, Lopinavir is the only 
PI with a fixed boosting dose of Ritonavir and known as Kaletra® (Hoffmann and 
Rockstroh, 2012). As of 2012, there are eight PIs approved by FDA and are actively used in 
hospitals (FDA, 2012).  
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HIV integrase integrates HIV DNA into human genome and is one of the crucial 
enzymes for HIV replication. Thus, integrase inhibitor was designed to stop integrase 
activity and prevent further spread of HIV infection. The first integrase inhibitor approved 
by FDA for treatment of HIV infection was Raltegravir on 2007 (McColl and Chen, 2010; 
FDA, 2012). Raltegravir is a strand transfer inhibitor that inhibits strand binding of viral 
DNA to cellular DNA. Moreover, Raltegravir is frequently used in salvage therapy for HIV 
patient, whose viruses had mutated and acquired resistance toward drugs from other classes. 
Elvitegravir is the second integrase inhibitor licensed recently in August 2012 by FDA and 
has the same role as Raltegravir (Hoffmann and Rockstroh, 2012).  
 
Entry inhibitors are the fifth ARV class, divided to three types based on how the 
drugs prevent HIV enters into CD4 T cells; attachment inhibitors, co-receptor antagonists 
(CXCR4 or CCR5), and fusion inhibitors. Maraviroc and Enfuvirtide (T-20) are the two 
currently available ARVs in this class. Maraviroc is an ARV in the co-receptor antagonists 
CCR5 class, bind to the CCR5 located on human cell surface and thus, blocking HIV protein 
gp120 from binding to CCR5 and preventing activation of entry mechanism (Hoffmann and 
Rockstroh, 2012). Co-receptor antagonists are the first ARV drugs which do not target the 
virus directly, instead they prevent viral entry into target cells. Enfuvirtide attaches to gp41 
to prevent the formation of an entry pore for the capsid of the virus, keeping it outside of the 
cell (Hoffmann and Rockstroh, 2012). HIV gp41 is a viral transmembrane protein that 
undergoes a conformational change to facilitate viral entry into target cells (Chan et al., 
1997). 
 
1.5.2 Combination therapy and HAART 
In the early period of ARV discovery, only one type of drug was used to treat HIV-infected 
patients, known as monotherapy. During that period, AZT was used as the sole drug to treat 
HIV infection and became the standard treatment for several years. However, it has been 
shown that HIV easily develops resistance following individual ARV therapies than when 
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combined multiple ARV drugs with varied mechanism of actions are administered. Dual 
therapy with AZT and (ddI or ddC) combination was later introduced and proven to be more 
effective than monotherapy (Zuckerman et al., 2009).  
 
Combination of different ARV is subject to positive and negative synergies and this 
consequently limits the number of effective combinations. At present, combination of 
abacavir and lamivudine (ABC + 3TC) or emtricitabine with tenofovir (FTC + TDF) are the 
most preferred choice for viral suppression compared with the rest of the NRTI drug 
combinations. AZT plus 3TC combination which was the most preferred combination in the 
1990s is now chosen as an alternative if the most preferred combination is not effective in 
patients (Hoffmann and Rockstroh, 2012). Gallant and co-workers (2006) claimed that FTC 
plus TDF is more effective and causing less frequent lipoathrophy but has equal infrequent 
resistance mutations and virological failure when compared with AZT plus 3TC. Outcomes 
from a study comparing ABC plus 3TC with FTC plus TDF showed insignificant differences 
between them in terms of virological efficacy and severe side effects (Gallant et al., 2006).  
 
There are several criteria need to be considered to formulate the best drug 
combination, which is level of efficacy, tolerability toward side effects and time taken for 
HIV to develop ARV resistance. There are several drug combinations that could result in 
lower efficacy become antagonistic to each other or have high probability to confer side 
effects such as mitochondrial toxicity and lipoatrophy, thus are not suggested to be used in 
the therapy especially for treatment-naive patients. For instance, FTC plus 3TC, ddI plus 
(d4T or TDF) and AZT plus d4T (Table 1.3) (Hoffmann and Rockstroh, 2012). 
Combinations of AZT plus d4T and FTC plus 3TC are antagonistic and must be avoided 
since both drugs compete for the same active site. Combination of ddI plus d4T or TDF also 
must be avoided due to high toxicity level since ddI is associated with long-term toxicity.  
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Table 1.3   Interaction between NRTI combinations. 
ARV 3TC ABC ddI d4T FTC TDF AZT 
3TC  +++ ++ + - ++ ++ 
ABC +++  0 0 0 0 + 
ddI + 0  - 0 - 0 
d4T + 0 -  0 0 - 
FTC - 0 0 0  +++ 0 
TDF ++ 0 - 0 +++  0 
AZT ++ + 0 - 0 0  
+++ preferred combination, ++ recommended as alternative, + other alternative, - pairing 
should be avoided, 0 insufficient data. 
Adapted from: Hoffmann and Rockstroh (2012) 
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Moreover, using d4T as part of drug combination is more associated with lipodystrophy. 
Therefore, combination of d4T with AZT or ddI should be used as the last resort for patient 
experiencing toxicities (Wormser, 2004). 
 
For pregnant women, the most preferred drug combination is AZT plus 3TC with 
Lopinavir/r (PIs), whereas Nevirapine and Efavirenz are an alternative to replace Lopinavir/r 
if the most preferred combination is not effective. However, Efavirenz is not recommended 
during first trimester since it may cause birth defects and should only be used during second 
and third trimester if it has an advantage over other drugs (Rathbun et al., 2012; AIDS info, 
2012). 
 
The availability of new drug classes such as NNRTI and PI has led to a more 
complex combination called “cocktail therapy” or highly active antiretroviral therapy 
(HAART). HAART was first introduced to the global market and Malaysia in 1999 and 
2002, respectively (Tee et al., 2006c). HAART usually involves a combination of at least 
three drugs from two or more classes of ARV treatment such as two NRTIs and one NNRTI 
(first-line treatment), two NRTIs and one PI (second-line treatment), two NRTIs and one 
integrase inhibitor (third-line treatment), two PIs and one or two NRTIs, one PI and one 
NNRTI with one or two NRTIs or other such combinations (Kayser et al., 2005). 
 
NNRTIs are extremely effective when combined with nucleoside analogues. 
Therefore, combination of one NNRTI and two NRTI is chosen as the first line treatment. 
The immunologic and virologic potency of NNRTIs in treatment-naive patients is almost 
equal to PIs. However, in treatment-experienced patients, the efficacy of NNRTIs is 
probably weaker compared with PIs (Hoffmann and Rockstroh, 2012). 
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 1.6 Antiviral drug resistance 
HIV drug resistance occurs if the virus could mutate and replicate itself in the presence of 
ARV drugs. Drug resistance leads to the treatment failure, spread of resistant strains of HIV, 
the need to develop new anti-HIV drugs and to change treatment strategy to second or third 
line treatment, resulting in increased of health costs. Using ineffective drugs will cause 
selective pressure which allows the resistant virus to replicate faster without the need to 
compete with other viruses that are sensitive to drugs. The mutated virus continues to 
replicate, able to retain mutations and could produce other mutations associated with drug 
resistance (Kessler, 2010). 
 
According to Pillay and co-workers (2000), despite good control of HIV infection by 
HAART, at least 50% of patients show virologic failure within the first year of treatment. 
There are several factors attributable to development of HIV drug resistance including poor 
adherence to ARV, infection with a resistance strains of HIV, superinfection and natural 
mutations during replication (Cane, 2005; Men´endez-Arias, 2008). Drug resistance can be 
achieved through the accumulation of one or more mutations in the viral target gene-coding 
region (pol, gag, env, integrase) (Men´endez-Arias, 2008).  
 
Poor adherence to drugs is the most common cause of initial drug resistance. This 
may involve in one particular drug or the entire regimen (Volberding, 2008). Non-
compliance of ARV drugs will cause incomplete suppression of viral replication, thus, 
allowing virus to overcome inhibition by drugs. Side effects of the drug, high burden to take 
complete drug dose and trouble swallowing pills are among several reasons why patients are 
not compliant with the therapy (AIDS info, 2012).  
 
Widespread use of HAART has successfully decrease morbidity and mortality of 
HIV infected patients. However, low ARV adherence has partly contributed to the 
emergence and spreading of resistance HIV strains to the newly-infected person. Emergence 
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of drug resistance HIV in treatment-naive patients were reported from several studies 
including Valle-Bahena et al. (2006), Babič et al. (2006), Stańczak et al. (2007), Toor et al. 
(2011) and Tseng et al. (2012). However, the prevalence of resistance to all drug classes is 
still low. 
 
Superinfection or multiple infections occur due to simultaneous infection with at 
least two heterologous strains (co-infection) or due to sequential infection, in which a second 
infection with a heterologous strain occurs after seroconversion to the primary infection has 
taken place (Hemelaar, 2012). There was a case reported in 2001, where a man with a 
primary HIV infection and no drug resistance observed had reported PI-resistance HIV from 
last blood taken. However, the patient denied taking any other antiretroviral medications 
especially PI, but he did report frequent unprotected anal receptive intercourse with partners 
of unknown HIV serostatus since his first HIV diagnosis (Smith et al., 2005). 
 
Lack of proofreading activity, high replication rate of approximately one billion 
virions per day and high mutation frequency especially in the HIV reverse transcriptase 
region contribute to natural resistance mutations (Martinez-Cajas and Wainberg, 2007). 
Previous studies have reported occurrence of mutations conferring resistance due to natural 
selection in protease (Holguin et al., 2004) and reverse transcriptase regions (Leal et al, 
2004). A study done by Leal and co-workers (2004) reported mutation A98G was retained in 
population for at least five years in the absence of continuous drug pressure.  
 
In Malaysia, the earliest drug resistance test was done by Tee et al. (2006a and 
2006c) for both treatment-naive and treated patient groups in Kuala Lumpur. Among 
treatment-naive patients, only one percent of them were reported having at least one major 
mutation conferring drug resistance in which was considered low prevalence (Tee et al., 
2006a). However, the prevalence of treated patients harboring at least one major mutation 
conferring resistance to NRTIs, NNRTIs, or PIs was high (77.8%) (Tee et al., 2006c), but 
